Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q3 2023 Earnings Presentation
24 slides from Arcticzymes Technologies Asa's earnings presentation, 2023
Slide 1: Q3 2023 Presentation
A ArcticZymes Technologies
Slide 2: Agenda
Agenda 1 Highlights – Q3 2023 2 Business Update 3 Financials 4 Q&A 5 Welcome to Michael Akoh
Slide 3: Highlights Q3 2023
Highlights Q3 2023 Drug Master File Achieved Quarterly New CEO (DMF) accepted Sales Michael Akoh 31.2 MNOK started Sept. SAN HQ GMP pre- 18th launch activities Brochure launched EBITDA Launched AZtaq™ Performance DNA Polymerase 7.3 MNOK
Slide 4: Building out the product portfolio
Building out the product portfolio Planned 2023 additions ✓ ArcticZymes Proteinase HQ Launched 18th April ✓ AZtaqTM (Taq DNA pol) Launched 10th Aug • DMF (Letter of Authorization) ✓ SAN HQ GMP • Pre-Marketing (Flyer, Website, YouTube)✓ • Applications Support (Brochure) ✓ • Launch Dec. 2023 T7 RNA po
Slide 5: 2024 product planning
Building out the product portfolio 2024 product planning T7 RNA polymerase HQ RNA Enzymes: Higher «HQ grade» Bioprocessing ‘ET-N1’ RNA Enzymes : Sequence specific riboendonuclease for RNA analytics SAN ELISA kit V2 Nucleases: Improved ELISA kit (SAN support product) M-SAN HQ GMP Nucleases: Strong ad
Slide 6: M-SAN HQ GMP nuclease activity vs salt
M-SAN HQ GMP Nuclease Activity at 150 mM NaCl, pH 7.5 Nuclease Activity (relative to self) vs. Salt (relative to M-SAN HQ) 100 M-SAN HQ 80 M-SAN HQ GMP Relative activity (%) Physiological 60 Salt SAN HQ GMP High 40 “de-aggregating” Salt 20 Benzonase 0 0 100 200 300 400 500 NaCl (mM) Lentivirus
Slide 7: Process validation of SAN HQ GMP for the DMF
Process validation of SAN HQ GMP for the DMF Highest priority for Operations in second half of 2023 The DMF will be further developed with amendment of the process validation to meet Commercial phase requirements Process validation in manufacturing: “The use of objective evidence to ascertain that a
Slide 8: Pre-Launch awareness activities for SAN HQ GMP
Pre-Launch awareness activities for SAN HQ GMP AWARENESS : July 6 - October, since filing DMF for SAN HQ GMP Extremely high TACTICS TARGETS RESULTS engagement Including 1. Visits to Landing Page: arciticzymes.com/ilovesalt Email LinkedIn 3500 Emails Sent Video etc. 52% Unique Open % vs industry av
Slide 9: New ArcticZymes website
New ArcticZymes website launching in November AS THE ENZYME EXPERTS We solve your challenges Our purpose is clear: advance the boundaries of molecular research, diagnostics, and therapeutics. We believe in redefining possibilities. The way we break through conventional limits is through specialized
Slide 10: Financials
Financials
Slide 11: Sales per area – Molecular Tools
Sales per area Sales per area – Molecular Tools Commercial 35 30 25 Molecular Tools 20 Sales in MNOK 15 ✓ Quarterly sales 15.3 MNOK ✓ Accounts for 48% of total Q3 sales 10 ✓ Research and Diagnostics contribution to Q3 sales were 12% and 27%, respectively 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021 202
Slide 12: Sales per area – Biomanufacturing
Sales per area Sales per area - Biomanufacturing Commercial 25 20 15 Biomanufacturing Sales in MNOK ✓ Quarterly sales 15.9 MNOK (0% change) 10 ✓ Accounts for 52% of total Q3 sales ✓ Challenging market conditions 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021 2021 2021 2021 2022 2022 2022 2022 2023 2023 2
Slide 13: 12 month rolling average quarterly sales
12 month rolling average quarterly sales «Steady state» sales 45 Sales development Sales growth is unchanged Sales development ex Covid-19 40 Number of orders increased from 343 in Q2 to 366 in Q3 35 21 new customers in Q3 30 25 MNOK …still uncertainty on short term market 20 movements Economic unce
Slide 14: Currency impact
Currency impact Continue to have positive contribution Majority of revenues are in foreign currency 74% in USD and 25% in EURO for Q3 79% in USD and 21% in EURO for 9M 68% in USD and 31% in EURO for 2022 Currency effect on P&L Finance 0.0 MNOK in Q3 and +0.4 MNOK 9 M 2023 Other operating expenses in
Slide 15: Expenses and profitability
Expenses and profitability
Slide 16: Organisation
Organisation No new hires in the pipeline Number of employees 70 Ambition and strategy has been to grow company organically 60 3 new position in Q3 65 employees per 30.09.2023 50 40 Administration 11 % 30 R&D 40 % Business development and 20 marketing 21 % 10 QA and 0 regulatory Operations 2019 2020
Slide 17: Profitability and expenses
Profitability and expenses Looking at improved profitability Sales & EBITDA 60 Sales EBITDA EBITDA 50 Q3 MNOK 7.3 vs 2.8 9M MNOK 20.2 vs 40.2 MNOK (25.2 Covid 40 adjusted) MNOK 30 Expenses decreased by 0.6 MNOK in Q3 and increased by 1.3 MNOK for 9 M 20 Personnel, consumables and IPR 10 Full year ex
Slide 18: Cash flow
Cash flow + 7.0 MNOK in cash flow for Q3 Cash position 30 Net Cash (MNOK) 250 25 Changes in Cash (MNOK) 20 240 15 Changes in cash (MNOK) Net Cash (MNOK) 230 10 5 220 - 5 210 - 10 200 - 15 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 18
Slide 19: Michael Akoh, CEO
Michael Akoh CEO
Slide 20: CEO Profile
CEO Profile Michael Benjamin Akoh Commercially focused life science executive ConvaTec, Oticon, Agilent, Wieslab IVD, Medical Devices, Biopharma drug development & diagnostic services Large corporations, scale ups & start-ups Leadership experience Scientific staffing and knowledge intensive solution
Slide 21: Why was I attracted to AZT?
Why was I attracted to AZT? Great platform for growth in an attractive market space! Market Operates in a market with significant growth opportunities Company Talented team and good culture Strategic, agile and decisive board Ambitious growth agenda Match of competencies Commercially focused life sc
Slide 22: The road forward: a focused and partner driven growth strategy
The road forward A focused and partner driven growth strategy Mission Creating a global leading specialist enzymes company A catalyst for innovation and progress for our partners Strategy Organic and inorganic growth strategy Expand core business and explore Biomanufacturing opportunities Innovation
Slide 23: Going forward!
Going forward! ”The course is set, the ship is solid, the engine powerful and the crew is capable.”
Slide 24: Thank you
A ArcticZymes Technologies
ArcticZymes Technologies — Q3 2023 Earnings Presentation on 6ix